Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Axsome Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.956 Good morning, and welcome to the Axiom Therapeutics fourth quarter and full year 2025 00:00:04.956 -- 00:00:10.923 earnings conference call. My name is Kevin, and I'll be your operator for today's call. 00:00:10.923 -- 00:00:13.946 At this time, all participants are in listen-only mode. 00:00:13.946 -- 00:00:16.869 Later, there will be a question-and-answer session, and instructions will be given at 00:00:16.869 -- 00:00:20.253 that time. Please note, this call is being recorded. 00:00:20.253 -- 00:00:25.519 I would now like to hand the floor to Ashley Dong, Director of Investor Relations. 00:00:25.519 -- 00:00:26.480 Ashley, please go ahead. 00:00:26.480 -- 00:00:28.262 Thank 00:00:28.262 -- 00:00:32.766 you. Good morning, and thank you all for joining Accent's fourth quarter and full year 00:00:32.766 -- 00:00:36.892 2025 earnings conference call. With us today are Dr. 00:00:36.892 -- 00:00:42.280 Ariel Tabuto, our Chief Executive Officer, Nick Pizzi, our Chief Financial Officer, 00:00:42.280 -- 00:00:47.568 and Ari Maizel, our Chief Commercial Officer, who will begin our call with prepared remarks. 00:00:47.568 -- 00:00:51.954 Mark Jacobson, our Chief Operating Officer, and Hunter Murdoch, our General Counsel, 00:00:51.954 -- 00:00:54.773 will also be available for Q&A. 00:00:54.773 -- 00:00:58.777 Before we begin, I encourage everyone to visit the investor section of our website to 00:00:58.777 -- 00:01:02.361 find the press release and presentation for today's call. 00:01:02.361 -- 00:01:06.084 Please note that today's discussion includes forward-looking statements regarding our 00:01:06.084 -- 00:01:11.330 financial performance, commercial strategy, and operational plans, including research, 00:01:11.330 -- 00:01:15.814 devel...